{"product_id":"tachiflutask-10bs-600mg-10mg","title":"TACHIFLUTASK*10BS 600MG+10MG","description":"\u003cp\u003e\u003cb\u003eTACHIFLUTASK 600 mg\/10 mg granulato in bustina\u003c\/b\u003e\u003cbr\u003e  Paracetamolo\/fenilefrina cloridrato\u003c\/p\u003e\u003cp\u003e\u003cb\u003eChe cos’è e a che cosa serve\u003c\/b\u003e\u003cbr\u003eTrattamento a breve termine dei sintomi da raffreddore ed influenza, inclusi il dolore di entità  lieve\/moderata e la febbre, quando associati a congestione nasale.\u003c\/p\u003e\u003cp\u003e\u003cb\u003eCosa deve sapere prima di prendere il medicinale\u003c\/b\u003e\u003cbr\u003e- Bambini di età inferiore ai 12 anni.\u003cbr\u003e  - Ipersensibilità ai principi attivi o ad uno qualsiasi degli eccipienti (elencati al paragrafo 6.1).\u003cbr\u003e  - Pazienti che assumono beta-bloccanti.\u003cbr\u003e  - Pazienti che assumono antidepressivi triciclici e quelli che assumono o hanno assunto nelle ultime 2  settimane inibitori delle monoamminoossidasi.\u003cbr\u003e  - Pazienti con asma bronchiale, feocromocitoma, glaucoma ad angolo chiuso, o che assumono  contemporaneamente altri medicinali simpatico mimetici (come decongestionanti, soppressori  dell'appetito e psicostimolanti simili alle amfetamine).\u003cbr\u003e  Pazienti affetti da insufficienza epatica o renale, diabete, ipertiroidismo, ipertensione e malattie  cardiovascolari.\u003cbr\u003e  - I prodotti a base di paracetamolo sono controindicati nei pazienti con manifesta insufficienza della  glucosio-6-fosfato deidrogenasi ed in quelli affetti da grave anemia emolitica.\u003cbr\u003e  - Grave insufficienza epatocellulare.\u003c\/p\u003e\u003cp\u003e\u003cb\u003eAvvertenze e precauzioni\u003c\/b\u003e\u003cbr\u003eI pazienti devono essere avvisati di non prendere altri medicinali contenenti paracetamolo mentre  assumono TACHIFLUTASK in quanto dosi elevate di paracetamolo possono causare reazioni avverse  gravi.\u003cbr\u003e  Evitare il consumo di alcool durante il trattamento con TACHIFLUTASK. Il pericolo di  sovradosaggio è infatti maggiore nei pazienti con problemi epatici.\u003cbr\u003e  Invitare il paziente a contattare il medico prima di associare warfarin o qualsiasi altro farmaco (vedere  anche il paragrafo 4.5).\u003cbr\u003e  È sconsigliato l'uso del prodotto se il paziente e in trattamento con antiinfiammatori.\u003cbr\u003e  Si consiglia cautela se il paracetamolo viene somministrato in concomitanza con flucloxacillina a  causa dell'aumentato rischio di acidosi metabolica con gap anionico elevato (HAGMA), in particolare  nei pazienti con grave compromissione renale, sepsi, malnutrizione e altre fonti di carenza di  glutatione (ad es. alcolismo cronico), così come in quelli che utilizzano le dosi massime giornaliere di  paracetamolo. Si raccomanda un attento monitoraggio, inclusa la misurazione della 5-oxoprolina  urinaria.\u003cbr\u003e  Consultare il medico prima di usare il prodotto in pazienti con ingrossamento della ghiandola  prostatica o malattie vascolari occlusive (ad es. sindrome di Raynaud).\u003cbr\u003e  Non superare la dose consigliata e non somministrare per oltre 3 giorni consecutivi.\u003cbr\u003e  TACHIFLUTASK contiene aspartame: tale sostanza può essere dannosa in soggetti affetti da  fenilchetonuria.\u003cbr\u003e  TACHIFLUTASK contiene meno di 1 mmol (23 mg) di sodio per compressa, cioè è essenzialmente  senza sodio.\u003c\/p\u003e\u003cp\u003e\u003cb\u003ePossibili effetti indesiderati\u003c\/b\u003e\u003cbr\u003e  Di seguito sono riportati gli effetti indesiderati organizzati secondo la classificazione per Sistemi ed  Organi MedDRA.\u003cbr\u003e  \u003cbr\u003e  La frequenza e cosi definita: molto comune (=1\/10), comune (da =1\/100 a \u0026lt;1\/10), non comune (da  =1\/1000 a \u0026lt;1\/100), raro (da =1\/10.000 a \u0026lt;1\/1000), molto raro (\u0026lt;1\/10.000), non nota (la frequenza non  può essere definita sulla base dei dati disponibili).\u003cbr\u003e  \u003cbr\u003e  \u003c\/p\u003e\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"3\"\u003e \u003ctr align=\"center\"\u003e\n\u003ctd\u003e\n\u003cb\u003eClassificazione per Sistemi ed Organi\u003c\/b\u003e \u003c\/td\u003e\n\u003ctd\u003e\u003cem\u003e\u003cb\u003eFrequenza\u003c\/b\u003e\u003c\/em\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cb\u003eEffetto indesiderato\u003c\/b\u003e\u003c\/td\u003e\n\u003c\/tr\u003e  \u003ctr\u003e\n\u003ctd rowspan=\"2\"\u003e\u003cb\u003ePatologie del sistema emolinfopoietico \u003c\/b\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cem\u003eRara\u003c\/em\u003e\u003c\/td\u003e\n\u003ctd\u003eAgranulocitosi\u003csup\u003e1\u003c\/sup\u003e, leucopenia\u003csup\u003e1\u003c\/sup\u003e, trombocitopenia\u003csup\u003e1\u003c\/sup\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e   \u003ctr\u003e\n\u003ctd\u003e\u003cem\u003eNon nota\u003c\/em\u003e\u003c\/td\u003e\n\u003ctd\u003eAnemia\u003csup\u003e1\u003c\/sup\u003e \u003c\/td\u003e\n\u003c\/tr\u003e   \u003ctr\u003e\n\u003ctd rowspan=\"2\"\u003e\u003cb\u003eDisturbi del sistema immunitario \u003c\/b\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cem\u003eRara\u003c\/em\u003e\u003c\/td\u003e\n\u003ctd\u003eReazioni allergiche\u003csup\u003e1,2\u003c\/sup\u003e, reazioni da ipersensibilità\u003csup\u003e1,2\u003c\/sup\u003e, anafilassi\u003csup\u003e1,2\u003c\/sup\u003e \u003c\/td\u003e\n\u003c\/tr\u003e   \u003ctr\u003e\n\u003ctd\u003e\u003cem\u003eNon nota\u003c\/em\u003e\u003c\/td\u003e\n\u003ctd\u003eShock anafilattico\u003csup\u003e1,2\u003c\/sup\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e   \u003ctr\u003e\n\u003ctd\u003e\u003cb\u003e Disturbi del metabolismo e  della nutrizione \u003c\/b\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cem\u003eComune \u003c\/em\u003e\u003c\/td\u003e\n\u003ctd\u003eAnoressia\u003csup\u003e2\u003c\/sup\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e   \u003ctr\u003e\n\u003ctd\u003e\u003cb\u003eDisturbi psichiatrici\u003c\/b\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cem\u003eMolto rara\u003c\/em\u003e\u003c\/td\u003e\n\u003ctd\u003eInsonnia\u003csup\u003e2\u003c\/sup\u003e, nervosismo\u003csup\u003e2\u003c\/sup\u003e, ansia\u003csup\u003e2\u003c\/sup\u003e, irrequietezza\u003csup\u003e2\u003c\/sup\u003e, confusione\u003csup\u003e2\u003c\/sup\u003e,  irritabilità\u003csup\u003e2\u003c\/sup\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e  \u003ctr\u003e\n\u003ctd\u003e\u003cb\u003ePatologie del sistema  nervoso\u003c\/b\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cem\u003eMolto rara\u003c\/em\u003e\u003c\/td\u003e\n\u003ctd\u003eTremore\u003csup\u003e2\u003c\/sup\u003e, capogiro\u003csup\u003e2\u003c\/sup\u003e, cefalea\u003csup\u003e2\u003c\/sup\u003e \u003c\/td\u003e\n\u003c\/tr\u003e   \u003ctr\u003e\n\u003ctd\u003e\u003cb\u003ePatologie dell'occhio\u003c\/b\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cem\u003eNon nota\u003c\/em\u003e\u003c\/td\u003e\n\u003ctd\u003eMidriasi\u003csup\u003e2\u003c\/sup\u003e, glaucoma acuto ad angolo chiuso\u003csup\u003e2\u003c\/sup\u003e \u003c\/td\u003e\n\u003c\/tr\u003e   \u003ctr\u003e\n\u003ctd\u003e\u003cb\u003ePatologie cardiache\u003c\/b\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cem\u003eRara\u003c\/em\u003e\u003c\/td\u003e\n\u003ctd\u003eTachicardia\u003csup\u003e2\u003c\/sup\u003e, palpitazioni\u003csup\u003e2\u003c\/sup\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e   \u003ctr\u003e\n\u003ctd\u003e\u003cb\u003ePatologie vascolari \u003c\/b\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cem\u003eNon nota\u003c\/em\u003e\u003c\/td\u003e\n\u003ctd\u003eIpertensione\u003csup\u003e2\u003c\/sup\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e   \u003ctr\u003e\n\u003ctd rowspan=\"2\"\u003e\u003cb\u003ePatologie respiratorie,  toraciche e mediastiniche\u003c\/b\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cem\u003eRara\u003c\/em\u003e\u003c\/td\u003e\n\u003ctd\u003eBroncospasmo\u003csup\u003e1,2\u003c\/sup\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e   \u003ctr\u003e\n\u003ctd\u003e\u003cem\u003eNon nota\u003c\/em\u003e\u003c\/td\u003e\n\u003ctd\u003eEdema della laringe\u003csup\u003e1\u003c\/sup\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e   \u003ctr\u003e\n\u003ctd rowspan=\"2\"\u003e\u003cb\u003ePatologie gastrointestinali\u003c\/b\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cem\u003eComune\u003c\/em\u003e\u003c\/td\u003e\n\u003ctd\u003eNausea\u003csup\u003e2\u003c\/sup\u003e, vomito\u003csup\u003e2\u003c\/sup\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e   \u003ctr\u003e\n\u003ctd\u003e\u003cem\u003eNon nota\u003c\/em\u003e\u003c\/td\u003e\n\u003ctd\u003eDiarrea\u003csup\u003e1\u003c\/sup\u003e, patologia gastrointestinale\u003csup\u003e1\u003c\/sup\u003e \u003c\/td\u003e\n\u003c\/tr\u003e   \u003ctr\u003e\n\u003ctd rowspan=\"2\"\u003e\u003cb\u003ePatologie epatobiliari\u003c\/b\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cem\u003eRara\u003c\/em\u003e\u003c\/td\u003e\n\u003ctd\u003eFunzione epatica anormale\u003csup\u003e1\u003c\/sup\u003e \u003c\/td\u003e\n\u003c\/tr\u003e   \u003ctr\u003e\n\u003ctd\u003e\u003cem\u003eNon nota\u003c\/em\u003e\u003c\/td\u003e\n\u003ctd\u003ePatologia epatica\u003csup\u003e1\u003c\/sup\u003e, epatite\u003csup\u003e1\u003c\/sup\u003e \u003c\/td\u003e\n\u003c\/tr\u003e   \u003ctr\u003e\n\u003ctd rowspan=\"2\"\u003e\u003cb\u003e Patologie della cute e del  tessuto sottocutaneo \u003c\/b\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cem\u003eRara\u003c\/em\u003e\u003c\/td\u003e\n\u003ctd\u003eEruzione cutanea\u003csup\u003e1,2\u003c\/sup\u003e, angioedema\u003csup\u003e2\u003c\/sup\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e   \u003ctr\u003e\n\u003ctd\u003e\u003cem\u003eNon nota\u003c\/em\u003e\u003c\/td\u003e\n\u003ctd\u003eNecrolisi tossica epidermica\u003csup\u003e1\u003c\/sup\u003e, Sindrome di Steven-Johnson\u003csup\u003e1\u003c\/sup\u003e, eritema multiforme o polimorfo\u003csup\u003e1\u003c\/sup\u003e \u003c\/td\u003e\n\u003c\/tr\u003e   \u003ctr\u003e\n\u003ctd rowspan=\"2\"\u003e\u003cb\u003ePatologie renali e urinarie\u003c\/b\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cem\u003eMolto rara\u003c\/em\u003e\u003c\/td\u003e\n\u003ctd\u003eNefrite tubulointerstiziale (dopo uso prolungato  del paracetamolo a dosi elevate)\u003csup\u003e1\u003c\/sup\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e   \u003ctr\u003e\n\u003ctd\u003e\u003cem\u003eNon nota\u003c\/em\u003e\u003c\/td\u003e\n\u003ctd\u003eInsufficienza renale aggravata\u003csup\u003e1\u003c\/sup\u003e, ematuria\u003csup\u003e1\u003c\/sup\u003e, anuria\u003csup\u003e1\u003c\/sup\u003e, ritenzione di urina \u003c\/td\u003e\n\u003c\/tr\u003e   \u003c\/table\u003e  \u003csup\u003e1\u003c\/sup\u003e Effetti indesiderati associati al paracetamolo\u003cbr\u003e  \u003csup\u003e2\u003c\/sup\u003e Effetti indesiderati associati alla fenilefrina\u003cbr\u003e  \u003cbr\u003e  Sono stati segnalati casi molto rari di reazioni cutanee gravi.\u003cbr\u003e  \u003cbr\u003e   \u003cb\u003eSegnalazione degli effetti indesiderati\u003c\/b\u003e\u003cbr\u003e Se manifesta un qualsiasi effetto indesiderato, compresi quelli non elencati in questo foglio, si rivolga al medico o al farmacista. Lei può inoltre segnalare gli effetti indesiderati direttamente tramite il sistema nazionale di segnalazione all’indirizzo: \u003cu\u003ehttps:\/\/www.aifa.gov.it\/content\/segnalazionireazioni-avverse\u003c\/u\u003e.\u003cbr\u003e Segnalando gli effetti indesiderati lei può contribuire a fornire maggiori informazioni sulla sicurezza di questo medicinale.\u003cp\u003e\u003ca href=\"https:\/\/www.salute.gov.it\/portale\/temi\/soggettoAutorizzatoVenditaOnlineFarmaciMDS.jsp?VOLID=F14409%20\" target=\"_blank\"\u003e\u003cimg src=\"http:\/\/www.farmania.it\/farmaco\/farmaco-promo-farmacia.png\"\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"ANGELINI PHARMA ITALIA SpA","offers":[{"title":"Default Title","offer_id":46290123718923,"sku":"047430018","price":7.98,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0748\/4683\/0859\/files\/GetDoc_0a193cb1-5157-4ed8-b7fe-d592285cb8db.png?v=1734080487","url":"https:\/\/farmaonline24.it\/en\/products\/tachiflutask-10bs-600mg-10mg","provider":"FarmaOnline24","version":"1.0","type":"link"}